• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

OPEX:开发一种新颖的总体患者体验衡量指标,以促进比较有效性研究的解释。

OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies.

机构信息

Department of Medicine, Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, United States of America.

Department of Medicine, Section of Rheumatology, Berkshire Health Systems, Pittsfield, Massachusetts, United States of America.

出版信息

PLoS One. 2021 Jan 29;16(1):e0245598. doi: 10.1371/journal.pone.0245598. eCollection 2021.

DOI:10.1371/journal.pone.0245598
PMID:33513209
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7846019/
Abstract

OBJECTIVES

A measure that encompasses both benefits and harms at the individual patient level may facilitate comparisons between treatment options and improve shared decision-making. The objective of this study was to develop a patient reported measure to capture overall experience (including both benefits and harms) of treatment using rheumatoid arthritis (RA) as a case example.

METHODS

Hierarchies for treatment benefits are known. Therefore, we developed a hierarchy of adverse events (AEs) using a series of trajectory mapping and paired comparison surveys. We subsequently used these data to construct a paired comparison survey, asking patients to compare options including both a specified level of benefit and an AE. These data were used to generate a hierarchy of overall experience on treatment.

RESULTS

782 participants completed a series of three surveys. The trajectory mapping procedure and a paired comparison survey led to the generation of a hierarchy of AEs with nine levels ranging from No AEs to irreversible serious complications. In a third survey, in which AEs were paired with benefits, participants' ratings generated a 6-level hierarchy of overall experiences ranging from Major improvement + No, mild or manageable AEs (Level 1) to No improvement + Irreversible AEs (Level 6).

CONCLUSIONS

Using a trajectory mapping approach, we developed a patient reported measure representing the distribution of patients' overall experiences on treatment. The intent of this measure is to enable patients and their physicians to compare the percentage of patients experiencing each level of outcome, from most to least desirable, across treatments.

摘要

目的

在个体患者层面上涵盖获益和危害的衡量指标可能有助于比较治疗选择,并改善共同决策。本研究的目的是开发一种患者报告的衡量指标,以捕捉使用类风湿关节炎(RA)作为案例的治疗的总体体验(包括获益和危害)。

方法

已知治疗获益的层次结构。因此,我们使用一系列轨迹映射和配对比较调查来构建不良事件(AE)的层次结构。随后,我们使用这些数据构建了配对比较调查,要求患者比较包括特定获益水平和 AE 的选项。这些数据用于生成治疗总体体验的层次结构。

结果

782 名参与者完成了一系列三项调查。轨迹映射程序和配对比较调查导致产生了一个 9 级的 AE 层次结构,范围从无 AE 到不可逆转的严重并发症。在第三次调查中,将 AE 与获益配对,参与者的评分生成了一个 6 级的总体体验层次结构,从获益大且无、轻度或可管理的 AE(第 1 级)到获益小或无且不可逆转的 AE(第 6 级)。

结论

使用轨迹映射方法,我们开发了一种患者报告的衡量指标,代表了患者治疗总体体验的分布。该衡量指标的目的是使患者及其医生能够比较不同治疗方法中每个体验水平的患者比例,从最理想到最不理想。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd87/7846019/7d54a7ad5603/pone.0245598.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd87/7846019/7d54a7ad5603/pone.0245598.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd87/7846019/7d54a7ad5603/pone.0245598.g001.jpg

相似文献

1
OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies.OPEX:开发一种新颖的总体患者体验衡量指标,以促进比较有效性研究的解释。
PLoS One. 2021 Jan 29;16(1):e0245598. doi: 10.1371/journal.pone.0245598. eCollection 2021.
2
Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis.药物不良反应对类风湿关节炎治疗和预防的影响。
Clin Ther. 2019 Jul;41(7):1376-1396. doi: 10.1016/j.clinthera.2019.04.030. Epub 2019 Jun 10.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Balneotherapy (or spa therapy) for rheumatoid arthritis.类风湿关节炎的温泉疗法(或水疗)
Cochrane Database Syst Rev. 2015 Apr 11;2015(4):CD000518. doi: 10.1002/14651858.CD000518.pub2.
5
Frequency and Impact of Adverse Events in Patients Undergoing Surgery for End-Stage Ankle Arthritis.终末期踝关节关节炎患者手术不良事件的发生率及影响
Foot Ankle Int. 2018 Sep;39(9):1028-1038. doi: 10.1177/1071100718776021. Epub 2018 May 31.
6
Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.中重度类风湿关节炎治疗决策的获益-风险权衡:关注患者视角。
Rheumatol Int. 2017 Sep;37(9):1423-1434. doi: 10.1007/s00296-017-3760-z. Epub 2017 Jun 16.
7
Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey.类风湿关节炎症状性不良反应的频率:一项探索性在线调查。
J Rheumatol. 2022 Sep;49(9):998-1005. doi: 10.3899/jrheum.210688. Epub 2022 Mar 1.
8
Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.群组认知行为方案对减轻类风湿关节炎疲劳的影响:RAFT RCT 伴有经济和定性评估。
Health Technol Assess. 2019 Oct;23(57):1-130. doi: 10.3310/hta23570.
9
Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys.比较类风湿关节炎管理中患者和医生的观点:来自全球医生和患者为基础的调查结果。
Health Qual Life Outcomes. 2018 Nov 9;16(1):211. doi: 10.1186/s12955-018-1035-3.
10

引用本文的文献

1
Supporting Health and Medical Decision Making: Findings and Insights from Fuzzy-Trace Theory.支持健康和医疗决策:来自模糊痕迹理论的发现和见解。
Med Decis Making. 2022 Aug;42(6):741-754. doi: 10.1177/0272989X221105473. Epub 2022 Jun 23.
2
The Application of Preference Elicitation Methods in Clinical Trial Design to Quantify Trade-Offs: A Scoping Review.偏好诱导方法在量化权衡的临床试验设计中的应用:一项范围综述。
Patient. 2022 Jul;15(4):423-434. doi: 10.1007/s40271-021-00560-w. Epub 2021 Dec 20.
3
Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions.

本文引用的文献

1
What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.“无”“轻度”“中度”“重度”和“极重度”对癌症患者意味着什么?PRO-CTCAE™反应量表的内容效度。
J Pain Symptom Manage. 2018 Mar;55(3):e3-e6. doi: 10.1016/j.jpainsymman.2017.10.024. Epub 2017 Nov 10.
2
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE)的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
3
自身免疫研究协作组的患者驱动型研究网络:基本原理、能力和未来方向。
Patient. 2021 Nov;14(6):699-710. doi: 10.1007/s40271-021-00515-1. Epub 2021 Apr 27.
4
Correction: OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies.更正:运营成本:开发一种新颖的总体患者体验测量方法以促进比较效果研究的解读。
PLoS One. 2021 Mar 9;16(3):e0248598. doi: 10.1371/journal.pone.0248598. eCollection 2021.
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).
结果排名的可取性(DOOR)和根据抗生素风险持续时间调整的反应(RADAR)。
Clin Infect Dis. 2015 Sep 1;61(5):800-6. doi: 10.1093/cid/civ495. Epub 2015 Jun 25.
4
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.戈利木单抗治疗甲氨蝶呤治疗应答不佳的活动性类风湿关节炎患者:GO-FORWARD 研究 52 周结果。
Ann Rheum Dis. 2010 Jun;69(6):1129-35. doi: 10.1136/ard.2009.116319. Epub 2010 May 5.
5
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.华法林抗凝治疗心房颤动的净临床获益。
Ann Intern Med. 2009 Sep 1;151(5):297-305. doi: 10.7326/0003-4819-151-5-200909010-00003.
6
A theory of medical decision making and health: fuzzy trace theory.一种医学决策与健康理论:模糊痕迹理论。
Med Decis Making. 2008 Nov-Dec;28(6):850-65. doi: 10.1177/0272989X08327066. Epub 2008 Nov 17.
7
Trajectory mapping: a new nonmetric scaling technique.轨迹映射:一种新的非度量缩放技术。
Perception. 1995;24(11):1315-31. doi: 10.1068/p241315.
8
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.美国风湿病学会类风湿关节炎临床试验疾病活动度测量初步核心指标集。类风湿关节炎临床试验结果测量委员会。
Arthritis Rheum. 1993 Jun;36(6):729-40. doi: 10.1002/art.1780360601.
9
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.乳腺癌辅助治疗的成本与效益:一项质量调整生存分析
J Clin Oncol. 1989 Jan;7(1):36-44. doi: 10.1200/JCO.1989.7.1.36.